Versaflex - MAM Cup - Spanish MAM T A Z A E N T R E N A D O R A - L E A R N T O D R I N K ™ • En cumplimiento de las normas de contacto con alimentos grasos de la Unión Europea* • Sensación de suavidad y tersura al tacto • Sin BPA, sin ftalatos • Gran facilidad de coloración • Ofreció una solución personalizada para cumplir con los Requerimientos de contacto con alimentos grasos y las necesidades de aplicación en Europa • Mejoró el atractivo para el cliente con un material suave, duradero y con color personalizado Versaflex™ FFC KEY REQUIREMENTS SOLUCIÓN AVIENT CUMPLE CON LA NORMATIVIDAD DE ALIMENTOS GRASOS MÁS INFORMACIÓN* Puede haber limitaciones: Consulte a Avient para obtener más información Copyright © 2020, Avient Corporation.

SPORTS BRAND S N O R K E L M O U T H P I E C E • Replace PVC with alternative materials such as TPE or silicone • Skin contact safety and UV resistance • Soft texture with a non-sticky feel • Translucent color to help children use it properly and safely • Customized a soft (Shore A) TPE solution that passed strict tests, including thermal deformation (80°C for 2 hours), UV resistance, and assembly resistance • Providing a 40% more cost-effective system than silicone due to the high production efficiencies of TPEs • Provided cross-regional cooperation and prompt response to help customers achieve fast commercialization in both Europe and China Versaflex Thermoplastic Elastomers UV RESISTANT + TRANSLUCENT Copyright © 2025, Avient Corporation.

ROSE Vice President, Corporate Communications Kyle Rose is Vice President, Corporate Communications at Avient Corporation, an innovator of materials solutions that help customers succeed while enabling a sustainable world.

Phil Clark is Senior Vice President, Chief Technology Officer, for Avient Corporation, the world’s premier provider of specialized and sustainable material solutions and services.

JOHN MIDEA Senior Vice President, Global Operations and Process Improvement John Midea is Senior Vice President, Global Operations and Process Improvement at Avient Corporation, an innovator of materials solutions that help customers succeed while enabling a sustainable world.

KRISTEN GAJEWSKI Chief Human Resources Officer Kristen Gajewski is Senior Vice President, Chief Human Resources Officer at Avient Corporation, an innovator of materials solutions that help customers succeed while enabling a sustainable world.

GIUSEPPE DI SALVO Vice President, Treasurer and Investor Relations Giuseppe “Joe” Di Salvo is Vice President, Treasurer and Investor Relations at Avient Corporation, an innovator of materials solutions that help customers succeed while enabling a sustainable world.

Microsoft PowerPoint - PolyOne Investor Presentation 5.4.20_v8 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • P E O P LE P RO D U CT S P LA N E T P E RF O R MAN C E •• •• •• JVs Performance Products & Solutions Distribution Specialty     To be the world’s premier provider of specialized polymer materials, services and solutions To be the world’s premier provider of specialized polymer materials, services and sustainable solutions • • • • • • • • • • • • • • 2016 2017 2018 2019 Lightweighting Reduced Material Requirements Improved Recyclability Renewable Energy Applications Eco-conscious Bio-derived Content Reduced Energy Use VOC Reduction $275M $325M $355M $410M 14% Total Annual Growth 9% Organic Annual Growth PolyOne Corporation 33 Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018*** Q1 2019*** 2019 Q1 2020 Net income from continuing operations attributable to PolyOne common shareholders Joint venture equity earnings, after tax Special items, before tax(1) Special items, tax adjustments(1) Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1 (19.0) (14.7) (3.7) — — — — — — — — — — — (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6 (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0) $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation. ** Pro forma for sale of Designed Structures and Solutions segment (DSS). *** Pro forma for sale of Performance Products and Solutions segment (PP&S).

Microsoft PowerPoint - PolyOne Investor Presentation 5.4.20_v8 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • P E O P LE P RO D U CT S P LA N E T P E RF O R MAN C E •• •• •• JVs Performance Products & Solutions Distribution Specialty     To be the world’s premier provider of specialized polymer materials, services and solutions To be the world’s premier provider of specialized polymer materials, services and sustainable solutions • • • • • • • • • • • • • • 2016 2017 2018 2019 Lightweighting Reduced Material Requirements Improved Recyclability Renewable Energy Applications Eco-conscious Bio-derived Content Reduced Energy Use VOC Reduction $275M $325M $355M $410M 14% Total Annual Growth 9% Organic Annual Growth PolyOne Corporation 33 Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018*** Q1 2019*** 2019 Q1 2020 Net income from continuing operations attributable to PolyOne common shareholders Joint venture equity earnings, after tax Special items, before tax(1) Special items, tax adjustments(1) Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1 (19.0) (14.7) (3.7) — — — — — — — — — — — (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6 (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0) $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation. ** Pro forma for sale of Designed Structures and Solutions segment (DSS). *** Pro forma for sale of Performance Products and Solutions segment (PP&S).

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified manufacturing sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal- derived substances • Standard concentrates in a PE carrier and on request in PP • Pre-colored formulations can be supplied in specific resins selected for the application REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) • Food contact established with FDA/EU* APPLICATION BULLETIN DRUG TYPE COLOR DESCRIPTION PANTONE REFERENCE AVIENT PRODUCT CODE PE BASED Adrenergic agonist combinations Light Green 373 C PE6M176349 Adrenergic agonists Purple 2583 C PE4M176057 Anti-infectives Tan 467 C PE8M176130 Anti-inflammatory, nonsteroidal Grey Cool Grey 4 C PE7M176184 Anti-inflammatory, steroids Pink 197 C PE3M176237 Anti-inflammatory, immunomodulators Olive Green 5763 C On request Beta-blockers Yellow Yellow C PE1M176160 Beta-blocker combinations Dark Blue 281 C PE5M176272 Carbonic anhydrase inhibitors Orange 1585 C PE2M176089 Cytotoxic Black 6 C PL9M176008 Miotics Dark Green 348 C PE6M176267 Mydriatics and cycloplegics Red 1797 C PE3M176236 Prostaglandin analogues Turquoise 326 C PE5M176273 Healthcare use limitations apply—see below. Processing conditions can cause material properties to shift from the values stated in the information. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.